While earlier studies have raised concerns about a possible increased risk of gallbladder disease with GLP-1 agonist use, emerging evidence suggests that these agents may exert beneficial effects on bile flow, inflammation, and metabolic homeostasis that could reduce the incidence of biliary complications in high-risk groups [11,12]. This evidence concerns the gene GCG and gallbladder disorder.